Current therapy of myelodysplastic syndromes |
| |
Authors: | Amer M. Zeidan Yuliya Linhares Steven D. Gore |
| |
Affiliation: | 1. Department of Oncology, the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University, Baltimore, MD 21287, USA;2. Blood and Marrow Transplant Program, the Samuel Oschin Comprehensive Cancer Institute at the Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA |
| |
Abstract: | After being a neglected and poorly-understood disorder for many years, there has been a recent explosion of data regarding the complex pathogenesis of myelodysplastic syndromes (MDS). On the therapeutic front, the approval of azacitidine, decitabine, and lenalidomide in the last decade was a major breakthrough. Nonetheless, the responses to these agents are limited and most patients progress within 2 years. Allogeneic stem cell transplantation remains the only potentially curative therapy, but it is associated with significant toxicity and limited efficacy. Lack or loss of response after standard therapies is associated with dismal outcomes. Many unanswered questions remain regarding the optimal use of current therapies including patient selection, response prediction, therapy sequencing and combinations, and management of resistance. It is hoped that the improved understanding of the underpinnings of the complex mechanisms of pathogenesis will be translated into novel therapeutic approaches and better prognostic/predictive tools that would facilitate accurate risk-adaptive therapy. |
| |
Keywords: | Myelodysplastic syndromes (MDS) Hypomethylating agents Azacitidine Decitabine Lenalidomide Immunosuppressive therapy Chemotherapy Erythropoiesis-stimulating agents Allogeneic stem cell transplantation |
本文献已被 ScienceDirect 等数据库收录! |
|